Lanodip Concentrate Teat Dip 3:1

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Available iodine

Disponível em:

Kilco (International) Ltd.

Código ATC:

QD08AG03

DCI (Denominação Comum Internacional):

Available iodine

Dosagem:

26.7 milligram(s)/millilitre

Forma farmacêutica:

Teat dip/spray solution

Tipo de prescrição:

LM: Licensed Merchant as defined in relevant national legislation

Grupo terapêutico:

Cattle

Área terapêutica:

iodine

Indicações terapêuticas:

Antiseptics

Status de autorização:

Authorised

Data de autorização:

2004-06-04

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Lanodip Concentrate Teat Dip 3:1
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE
Iodine
26.7
mg
(Available Iodine 21.0 mg)
For a full list of excipients see section 6.1
3 PHARMACEUTICAL FORM
Teat Dip / Spray Solution.
A dark brown liquid.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Lactating dairy cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
As an aid in the prevention of mastitis in lactating dairy cattle.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Teat dip cups should be emptied after each milking and washed
thoroughly before re-use.
Wash and dry udders and teats before next milking.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS
Do not eat, drink or smoke whilst using the product.
Wash hands after use.
When the product is being applied through spray equipment avoid
working in spray mist.
In case of contact with eyes, give prolonged irrigation with clean
water and seek medical attention. In case of ingestion,
seek medical attention immediately.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_4_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_2_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_1_
_9_
_2_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.6 ADVERSE REACTIONS (FREQUENCY AND SERI